Cargando…

Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma

INTRODUCTION: Glioblastoma (GBM) is the most lethal primary malignant brain tumor in adults with poor survival due to acquired therapeutic resistance and rapid recurrence. Currently, the standard clinical strategy for glioma includes maximum surgical resection, radiotherapy, and temozolomide (TMZ) c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jia, Zuo, Jie, Wahafu, Alafate, Wang, Mao‐de, Li, Rui‐chun, Xie, Wan‐fu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053231/ https://www.ncbi.nlm.nih.gov/pubmed/31318172 http://dx.doi.org/10.1111/cns.13197

Ejemplares similares

Elevation of CXCL1 indicates poor prognosis and radioresistance by inducing mesenchymal transition in glioblastoma
por: Alafate, Wahafu, et al.
Publicado: (2020)

Retraction: Receptor tyrosine kinase AXL is correlated with poor prognosis and induces temozolomide resistance in glioblastoma
por: Wang, Jia, et al.
Publicado: (2019)

Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide
por: Sun, Stella, et al.
Publicado: (2012)

Elevated XRCC5 expression level can promote temozolomide resistance and predict poor prognosis in glioblastoma
por: Lee, I-Neng, et al.
Publicado: (2021)

Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling
por: Alafate, Wahafu, et al.
Publicado: (2020)

Aberrant Expression of ADARB1 Facilitates Temozolomide Chemoresistance and Immune Infiltration in Glioblastoma
por: Lu, Can, et al.
Publicado: (2022)

Hypoxanthine phosphoribosyl transferase 1 metabolizes temozolomide to activate AMPK for driving chemoresistance of glioblastomas
por: Yin, Jianxing, et al.
Publicado: (2023)

MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype
por: Yan, Wei, et al.
Publicado: (2015)

Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
por: Wang, Ke, et al.
Publicado: (2017)

Tbx2 confers poor prognosis in glioblastoma and promotes temozolomide resistance with change of mitochondrial dynamics
por: Yi, Fuxin, et al.
Publicado: (2017)

Preoperative Prediction Nomogram Based on Integrated Profiling for Glioblastoma Multiforme in Glioma Patients
por: Wu, Wei, et al.
Publicado: (2020)

TRIB3 facilitates glioblastoma progression via restraining autophagy
por: Tang, Zhanbin, et al.
Publicado: (2020)

AKT2-knockdown suppressed viability with enhanced apoptosis, and attenuated chemoresistance to temozolomide of human glioblastoma cells in vitro and in vivo
por: Cui, Yong, et al.
Publicado: (2015)

Elevated RGMA Expression Predicts Poor Prognosis in Patients with Glioblastoma
por: Phan, Thi Le, et al.
Publicado: (2021)

NEK2 enhances malignancies of glioblastoma via NIK/NF-κB pathway
por: Xiang, Jianyang, et al.
Publicado: (2022)

Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells
por: Cheng, Quan, et al.
Publicado: (2017)

Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma
por: Zhang, Zhuoran, et al.
Publicado: (2019)

Downregulated ferroptosis‐related gene SQLE facilitates temozolomide chemoresistance, and invasion and affects immune regulation in glioblastoma
por: Yao, Lei, et al.
Publicado: (2022)

Tumor Microenvironment and Genes Affecting the Prognosis of Temozolomide-Treated Glioblastoma
por: Jang, Yena, et al.
Publicado: (2023)

Poor-Prognosis Patients Affected by Glioblastoma: Retrospective Study of Hypofractionated Radiotherapy with Simultaneous Integrated Boost and Concurrent/Adjuvant Temozolomide
por: Gregucci, Fabiana, et al.
Publicado: (2021)

Tumour exosomes from cells harbouring PTPRZ1–MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma
por: Zeng, A-L, et al.
Publicado: (2017)

Long noncoding RNA GIHCG induces cancer progression and chemoresistance and indicates poor prognosis in colorectal cancer
por: Jiang, Xiaohua, et al.
Publicado: (2019)

Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA‐101 in glioblastoma
por: Cai, Tao, et al.
Publicado: (2018)

Aberrant Transcriptional Regulation of Super-enhancers by RET Finger Protein-histone Deacetylase 1 Complex in Glioblastoma: Chemoresistance to Temozolomide
por: NATSUME, Atsushi, et al.
Publicado: (2019)

Elevated expression of pancreatic adenocarcinoma upregulated factor (PAUF) is associated with poor prognosis and chemoresistance in epithelial ovarian cancer
por: Choi, Chel Hun, et al.
Publicado: (2018)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide Era
por: Carico, Christine, et al.
Publicado: (2012)

Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients
por: Shields, Lisa B. E., et al.
Publicado: (2015)

Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells
por: Hellmold, Dana, et al.
Publicado: (2023)

Abnormal expression of TRIB3 in colorectal cancer: a novel marker for prognosis
por: Miyoshi, N, et al.
Publicado: (2009)

STAT3-mediated upregulation of LINC00520 contributed to temozolomide chemoresistance in glioblastoma by interacting with RNA-binding protein LIN28B
por: Yuan, Shuai, et al.
Publicado: (2022)

FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells
por: Lin, Jing, et al.
Publicado: (2018)

ACT-10 TREATMENT FOR GLIOBLASTOMA RECURRED AFTER CONCOMITANT CHEMORADIATION THERAPY WITH TEMOZOLOMIDE AND THEIR PROGNOSIS
por: Mori, Kanji, et al.
Publicado: (2019)

Elevated LSD1 and SNAIL Expression Indicate Poor Prognosis in Hypopharynx Carcinoma
por: Bottner, Justus, et al.
Publicado: (2022)

Accelerated hyperfractionation plus temozolomide in glioblastoma
por: Kaul, David, et al.
Publicado: (2016)

Strategies of temozolomide in future glioblastoma treatment
por: Lee, Chooi Yeng
Publicado: (2017)

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
por: Saha, Dipongkor, et al.
Publicado: (2020)

MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression
por: Chen, Wei, et al.
Publicado: (2017)

TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT
por: Nie, Er, et al.
Publicado: (2020)

Elevated M-MDSCs in Circulation Are Indicative of Poor Prognosis in Diffuse Large B-Cell Lymphoma Patients
por: Wang, Zhitao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fivogt1h7ll182d4ffgkm2oah6